Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Phase 3

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: gemcitabine
Drug: disitamab vedotin
Drug: pembrolizumab
Drug: cisplatin
Drug: carboplatin

First Posted Date: 2024-06-12

Last Posted Date: 2025-04-17

Lead Sponsor: Seagen Inc.

Target Recruit Count: 98

Registration Number: 2022-501105-12-00

Locations: 🇦🇹
Medical University Of Graz, Graz, Austria
🇦🇹
Medical University Of Vienna, Vienna, Austria
🇦🇹
Stadt Wien Wiener Gesundheitsverbund, Vienna, Austria

and more 87 locations

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Recruiting

Conditions: Urothelial Carcinoma

First Posted Date: 2023-06-15

Last Posted Date: 2025-06-26

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 350

Registration Number: NCT05902494

Locations: 🇫🇷
Chu Bordeaux Hopital Saint Andre, BORDEAUX Cedex, France
🇫🇷
Centre Hospitalier Départemental Les Oudairies, La Roche Sur Yon Cedex 9, France
🇫🇷
Centre Antoine Lacassagne, Nice, France

and more 20 locations

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Phase 1

Active, not recruiting

Conditions: Non-small Cell Lung Cancer
Pancreatic Neoplasms
Mesothelioma
Cutaneous Melanoma
Colorectal Neoplasms

Interventions: Drug: PF-08046049

First Posted Date: 2022-10-07

Last Posted Date: 2025-06-10

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 41

Registration Number: NCT05571839

Locations: 🇺🇸
Presbyterian/St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸
BWH, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 38 locations

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Phase 3

Recruiting

Conditions: Colorectal Neoplasms

Interventions: Drug: tucatinib
Drug: bevacizumab
Drug: trastuzumab
Drug: cetuximab
Drug: oxaliplatin
Drug: leucovorin
Drug: levoleucovorin
Drug: fluorouracil

First Posted Date: 2022-02-24

Last Posted Date: 2025-06-17

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 400

Registration Number: NCT05253651

Locations: 🇺🇸
Palo Verde Hematology Oncology, Glendale, Arizona, United States
🇺🇸
Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States

and more 353 locations

A Safety Study of Brentuximab Vedotin in Participants With HIV

Phase 1

Withdrawn

Conditions: Human Immunodeficiency Virus

Interventions: Drug: Placebo
Drug: brentuximab vedotin
Drug: ART

First Posted Date: 2022-02-17

Last Posted Date: 2023-02-14

Lead Sponsor: Seagen Inc.

Registration Number: NCT05244473

Locations: 🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

A Study of SGN-ALPV in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Ovarian Neoplasms
Endometrial Neoplasms
Carcinoma, Non-Small-Cell Lung
Stomach Neoplasms
Gastroesophageal Junction Carcinoma
Uterine Cervical Neoplasms
Testicular Neoplasms

Interventions: Drug: SGN-ALPV

First Posted Date: 2022-02-08

Last Posted Date: 2025-02-10

Lead Sponsor: Seagen Inc.

Target Recruit Count: 43

Registration Number: NCT05229900

Locations: 🇺🇸
Women's Cancer Care, Fresno, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Florida Cancer Specialists - Lake Nona, Wellington, Florida, United States

and more 10 locations

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Melanoma
Esophageal Squamous Cell Carcinoma
Ovarian Neoplasms
Triple Negative Breast Neoplasms
Gastric Cancer

Interventions: Drug: PF-08046054
Drug: pembrolizumab

First Posted Date: 2022-01-26

Last Posted Date: 2025-06-03

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 315

Registration Number: NCT05208762

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, IDS Pharmacy, Birmingham, Alabama, United States

and more 39 locations

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Ovarian Neoplasms
Peritoneal Neoplasms
Fallopian Tube Neoplasms
Triple Negative Breast Neoplasms
HER2 Negative Breast Neoplasms
Hormone Receptor Positive Breast Neoplasms
Endometrial Neoplasms
Carcinoma, Non-Small-Cell Lung
Cholangiocarcinoma
Gallbladder Carcinoma

Interventions: Drug: Felmetatug Vedotin
Drug: Pembrolizumab

First Posted Date: 2022-01-18

Last Posted Date: 2025-06-19

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 246

Registration Number: NCT05194072

Locations: 🇺🇸
UCHealth Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, United States
🇺🇸
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
🇺🇸
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States

and more 22 locations

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Phase 3

Active, not recruiting

Conditions: HER2 Positive Breast Cancer

Interventions: Drug: Tucatinib
Drug: Pertuzumab
Drug: Trastuzumab
Drug: Placebo

First Posted Date: 2021-11-24

Last Posted Date: 2025-06-03

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 654

Registration Number: NCT05132582

Locations: 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸
CARTI Cancer Center,Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, United States

and more 350 locations

A Study of SEA-CD40 Given With Other Drugs in Cancers

Phase 2

Completed

Conditions: Carcinoma, Non-Small- Cell Lung
Melanoma

Interventions: Drug: SEA-CD40
Drug: pembrolizumab (KEYTRUDA®)
Drug: pemetrexed
Drug: carboplatin

First Posted Date: 2021-08-06

Last Posted Date: 2025-05-11

Lead Sponsor: Seagen Inc.

Target Recruit Count: 77

Registration Number: NCT04993677

Locations: 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
California Pacific Medical Center Research Institute/Sutter Medical Centre, San Francisco, California, United States

and more 26 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy